Denali Therapeutics

DNLI

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Denali Therapeutics is a biotechnology company focused on developing treatments for neurodegenerative diseases — conditions where the brain and nervous system slowly break down over time. Its main research targets diseases like Alzheimer's, Parkinson's, and ALS. The company is based in South San Francisco and is considered a clinical-stage biotech, meaning it does not yet sell approved medicines to patients.

Denali makes almost no revenue today and funds its work primarily through partnerships with large pharmaceutical companies, including a significant collaboration with Sanofi. It has developed a proprietary platform called the Transport Vehicle (TV) technology, designed to help drugs cross the blood-brain barrier — a major scientific challenge in treating brain diseases. This technology is its core competitive asset, but the company burns through cash while its drugs move through clinical trials, and failure of key pipeline programs remains the central risk to the business.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+5.6% YoY

YoY Growth Rate

Slow EPS growth

Insider Activity

9.1%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~12 months

$940M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

0.0%

Thin — 0.0% gross margin

Profit after running costs

Operating Margin

-3622.1%

Losing money on operations — -3622.1%

Return on the money invested

ROCE

-65.0%

Weak — -65.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-15923.5%

Burning cash (-15923.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial